Oppenheimer maintains Artivion stock with $32 target

On Monday, Oppenheimer reiterated its positive stance on Artivion Inc. (NYSE:AORT), maintaining an Outperform rating and a $32.00 price target. The endorsement comes on the heels of Artivion's presentation of new clinical data over the weekend. Currently trading at $30.95, the stock has delivered an impressive 82.17% return over the past year and is approaching its 52-week high of $32.33. According to InvestingPro analysis, analysts maintain a Strong Buy consensus with price targets ranging from $32 to $35. Artivion showcased one-year follow-up results from its PERSEVERE study, which assesses the performance of its Aortic Molding Device System (AMDS) in patients with acute DeBakey Type I dissection and malperfusion.

The PERSEVERE study, involving 93 patients, highlighted that AMDS demonstrated favorable outcomes when compared to traditional hemiarch repair. Notably, the occurrence of strokes in patients treated with AMDS was less than 50% of that in the control group, and there were no reported device-associated new entry (DANE) tears. Additionally, the data indicated positive aortic remodeling outcomes.

These findings build upon the encouraging 30-day data previously released and Artivion's announcement in early December that the FDA had granted AMDS a Humanitarian Device Exemption. This exemption allows for the device to be used in the treatment of conditions affecting fewer than 8,000 individuals in the United States per year.

The analyst from Oppenheimer highlighted that the strong clinical results support the AMDS's price point of approximately $25,000. With an estimated total addressable market of around 5,000 cases annually across 1,000 U.S. hospitals, the device's market potential appears significant. InvestingPro data shows Artivion's current market capitalization at $1.3 billion, with robust revenue growth of 13.29% in the last twelve months. Subscribers to InvestingPro can access the comprehensive Pro Research Report for deeper insights into Artivion's financial health and growth prospects.

Investors and analysts alike are anticipating further insights to be shared on Artivion's upcoming fourth-quarter earnings call, scheduled for February 13, 2025. The company's recent developments and the sustained analyst endorsement suggest a continued focus on the commercialization and clinical advancement of its AMDS device. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with 8 additional ProTips available to subscribers.

In other recent news, Artivion Inc. reported significant findings from its PERSEVERE study, highlighting the effectiveness of its AMDS device in patients with acute DeBakey Type I dissection. The study, reaffirmed by Oppenheimer, showed that the device led to a lower stroke occurrence and evidence of positive aortic remodeling. Furthermore, the FDA granted the AMDS a Humanitarian Device Exemption, reinforcing its potential market impact.

Artivion also disclosed a cybersecurity incident but stated it does not anticipate a material impact. In terms of financial performance, Artivion reported a 10% year-over-year increase in Q3 2024 revenue to $95.8 million, with an adjusted EBITDA rise of 28% to $17.7 million. For the full year, the company anticipates a revenue growth of 10% to 12%, with projected revenues between $389 million and $396 million.

These recent developments, including the filing of the first module of the AMDS PMA and NMPA approval for BioGlue in China, suggest a solid growth trajectory for Artivion. Analysts have discussed a $20 million opportunity related to BioGlue in China, with significant progress expected in H2 2025. Despite some challenges, these recent developments suggest a solid growth trajectory for Artivion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.